Jyvaskyla – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 28 Aug 2026 04:33:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Jyvaskyla – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence https://clinicaltrials.eu/trial/study-comparing-imlunestrant-with-standard-endocrine-therapy-for-patients-with-early-er-her2-breast-cancer-at-increased-risk-of-recurrence/ Wed, 19 Aug 2026 04:02:58 +0000 https://clinicaltrials.eu/trial/study-comparing-imlunestrant-with-standard-endocrine-therapy-for-patients-with-early-er-her2-breast-cancer-at-increased-risk-of-recurrence/ This clinical trial is focused on studying treatments for early-stage breast cancer, specifically for patients who have a type of breast cancer known as ER-positive and HER2-negative. These terms refer to the presence of certain receptors on cancer cells that can influence how the cancer grows and responds to treatment. The study is comparing a new treatment called imlunestrant with standard treatments that are commonly used to block the effects of estrogen, a hormone that can promote the growth of some breast cancers. The standard treatments being compared include medications like tamoxifen, exemestane, anastrozole, letrozole, and gonadotropin-releasing hormone analogues.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

]]> Apixaban for Preventing Blood Clots in Adults Receiving Neoadjuvant Therapy for Muscle‑Invasive Bladder Cancer https://clinicaltrials.eu/trial/apixaban-for-preventing-blood-clots-in-adults-receiving-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer/ Mon, 03 Aug 2026 10:46:08 +0000 https://clinicaltrials.eu/trial/apixaban-for-preventing-blood-clots-in-adults-receiving-neoadjuvant-therapy-for-muscle-invasive-bladder-cancer/ In this study the focus is on patients with muscle‑invasive bladder cancer who are receiving treatment before surgery or radiation, called neoadjuvant therapy. The trial looks at whether adding the blood‑thinning medicine apixaban, an oral factor Xa inhibitor, can reduce the chance of developing venous thromboembolism (a clot that forms in a vein) compared with not giving any extra blood thinner. The usual cancer medicines that may be used before the main treatment include combinations such as gemcitabine‑cisplatin, MVAC, durvalumab with gemcitabine‑cisplatin, or enfortumab vedotin together with pembrolizumab. The main surgical option is a radical cystectomy, while an alternative is chemoradiotherapy.

The purpose of the study is to find out if the addition of the blood thinner provides more benefit than harm in these patients. Participants are randomly assigned to either receive a daily 5 mg dose of apixaban or to receive no extra blood‑thinning medication while they undergo their standard cancer treatment. Throughout the treatment period, patients have regular check‑ups and a special X‑ray picture called a CT scan to look for any clots or serious bleeding. The term major bleeding refers to serious bleeding that may need a blood transfusion, occur in a vital organ, cause a large drop in blood‑protein levels (hemoglobin), or be life‑threatening.

After the neoadjuvant therapy and before the definitive surgery or radiation, patients continue to be monitored for several months to see if clots or serious bleeding occur, and longer‑term follow‑up looks at overall survival and cancer‑specific outcomes.

]]> Evaluating the effect of recombinant varicella zoster virus glycoprotein E on the risk of dementia in adults aged 76 years and older https://clinicaltrials.eu/trial/evaluating-the-effect-of-recombinant-varicella-zoster-virus-glycoprotein-e-on-the-risk-of-dementia-in-adults-aged-76-years-and-older/ Mon, 03 Aug 2026 10:43:19 +0000 https://clinicaltrials.eu/trial/evaluating-the-effect-of-recombinant-varicella-zoster-virus-glycoprotein-e-on-the-risk-of-dementia-in-adults-aged-76-years-and-older/ This study is designed to evaluate the effect of the Shingrix vaccine on the risk of developing dementia, a condition that affects memory, thinking, and reasoning skills. The research focuses on whether receiving this vaccine, which is used to prevent Herpes zoster, also helps in preventing a new diagnosis of this brain-related condition in older adults.

Participants in the study will be assigned to receive either the Shingrix vaccine or a placebo. The Shingrix is a recombinant vaccine, which means it is made using a specific piece of the virus to help the body build protection. The placebo used in this trial is a saline solution, which is a simple mixture of salt and water. The medication will be given as an intramuscular injection, meaning it is delivered directly into the muscle.

]]> A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin https://clinicaltrials.eu/trial/a-study-comparing-cagrilintide-and-semaglutide-combination-to-semaglutide-cagrilintide-and-placebo-in-adults-with-type-2-diabetes-on-metformin/ Mon, 03 Aug 2026 10:42:15 +0000 https://clinicaltrials.eu/trial/a-study-comparing-cagrilintide-and-semaglutide-combination-to-semaglutide-cagrilintide-and-placebo-in-adults-with-type-2-diabetes-on-metformin/ This study is looking at people with type 2 diabetes whose blood sugar levels are not well controlled with their current medication. Type 2 diabetes is a condition where the body does not properly use insulin, a hormone that helps control blood sugar levels. The study will test different combinations and doses of medications given as injections under the skin. These medications include cagrilintide, semaglutide, a combination of both called CagriSema, and placebo. Some participants may also continue taking their regular diabetes medications, which could include metformin taken by mouth, with or without a type of medication called an SGLT2 inhibitor such as dapagliflozin.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

]]> A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation https://clinicaltrials.eu/trial/a-study-comparing-ziltivekimab-to-placebo-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction-and-inflammation/ Mon, 03 Aug 2026 10:40:44 +0000 https://clinicaltrials.eu/trial/a-study-comparing-ziltivekimab-to-placebo-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction-and-inflammation/ This study involves people with heart failure who have either mildly reduced or preserved ejection fraction, which means their heart is not pumping blood as well as it should but has not severely weakened. Ejection fraction is a measurement that shows how much blood the heart pumps out with each beat. The study also focuses on people who have inflammation in their body, which is a condition where the body’s immune system is more active than normal and can be measured by certain blood tests. The treatment being tested is called ziltivekimab, which is given as an injection under the skin once a month. Some people in the study will receive ziltivekimab while others will receive placebo, and both groups will continue taking their regular heart failure medications.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

]]> Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease https://clinicaltrials.eu/trial/study-of-vicadrostat-and-empagliflozin-combination-in-patients-with-type-2-diabetes-high-blood-pressure-and-cardiovascular-disease/ Mon, 03 Aug 2026 10:39:34 +0000 https://clinicaltrials.eu/trial/study-of-vicadrostat-and-empagliflozin-combination-in-patients-with-type-2-diabetes-high-blood-pressure-and-cardiovascular-disease/ This study focuses on people who have three medical conditions: Type 2 diabetes, hypertension (high blood pressure), and cardiovascular disease (heart and blood vessel disease). The research examines a combination of two medications: empagliflozin (Jardiance) and vicadrostat (BI 690517), compared to treatment with empagliflozin and placebo. Both medications are taken as tablets by mouth.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

]]> Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-to-reduce-cardiovascular-problems-in-overweight-or-obese-patients-with-atherosclerotic-cardiovascular-disease/ Mon, 03 Aug 2026 10:39:00 +0000 https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-to-reduce-cardiovascular-problems-in-overweight-or-obese-patients-with-atherosclerotic-cardiovascular-disease/ This study focuses on people with atherosclerotic cardiovascular disease (a condition where arteries become hardened and narrowed) who are also overweight or have obesity. The purpose is to evaluate whether a new medication called maridebart cafraglutide (also known as AMG 133) can help reduce heart and blood vessel-related health problems compared to placebo when added to standard treatments.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

]]> Study Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol https://clinicaltrials.eu/trial/study-comparing-intravenous-contrast-ct-with-non-contrast-ct-for-patients-with-acute-abdominal-pain-and-reduced-kidney-function-using-iohexol/ Mon, 03 Aug 2026 10:38:34 +0000 https://clinicaltrials.eu/trial/study-comparing-intravenous-contrast-ct-with-non-contrast-ct-for-patients-with-acute-abdominal-pain-and-reduced-kidney-function-using-iohexol/ This clinical trial is focused on patients experiencing an acute abdomen, which refers to sudden and severe abdominal pain that may require urgent medical attention. The study is particularly interested in patients who also have impaired renal function, meaning their kidneys are not working as well as they should. The trial will compare two types of computed tomography (CT) scans: one using an intravenous (IV) contrast called Omnipaque, which contains the active substance iohexol, and the other without any contrast.

The purpose of the study is to determine if using the IV contrast CT is better at diagnosing the cause of acute abdomen in these patients compared to a CT scan without contrast. Participants will be randomly assigned to receive either the contrast-enhanced CT or the non-contrast CT. The study will monitor participants for up to 90 days to observe outcomes such as overall survival, the need for kidney support treatments, and any changes in kidney function.

Throughout the study, researchers will also look at other factors, such as the severity of any acute kidney injury (AKI)</b) that might occur, any organ dysfunction, and the number of days participants spend out of the hospital. The study aims to provide valuable information on the best imaging approach for patients with acute abdomen and impaired kidney function, potentially improving diagnosis and treatment strategies in the future.

]]> Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-high-dose-influenza-vaccine-in-adults-aged-60-and-over-comparing-trivalent-influenza-vaccine-with-a-drug-combination/ Mon, 03 Aug 2026 10:38:27 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-high-dose-influenza-vaccine-in-adults-aged-60-and-over-comparing-trivalent-influenza-vaccine-with-a-drug-combination/ This clinical trial is focused on studying the effectiveness and safety of a new high-dose vaccine for influenza, commonly known as the flu, in adults aged 60 and older. The study will compare Abbott’s candidate high-dose vaccine, known as Trivalent Influenza Vaccine – High Dose (TIV-HD), with an existing vaccine called Efluelda. Both vaccines are designed to protect against three different strains of the influenza virus, which are updated regularly to match the most common strains circulating each flu season.

The purpose of the study is to determine if the new high-dose vaccine is at least as effective as the existing vaccine in producing an immune response. Participants will receive either the new vaccine or the existing one through an injection. The study will monitor the immune response by measuring specific antibodies in the blood 28 days after vaccination. Participants will also be observed for any side effects or adverse reactions following the vaccination.

The study will take place over several months, with participants being followed up to six months after receiving the vaccine. This will help researchers gather comprehensive data on the vaccine’s safety and its ability to trigger a strong immune response. The ultimate goal is to ensure that the new high-dose vaccine provides effective protection against influenza in older adults, who are at higher risk for complications from the flu.

]]> Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-menacyw-conjugate-vaccine-compared-to-a-drug-combination-in-healthy-infants-and-toddlers/ Mon, 03 Aug 2026 10:37:40 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-menacyw-conjugate-vaccine-compared-to-a-drug-combination-in-healthy-infants-and-toddlers/ This clinical trial is focused on studying the effectiveness and safety of a vaccine for preventing meningococcal infection in healthy infants and toddlers. Meningococcal infection is a serious illness caused by bacteria that can lead to infections in the brain and spinal cord. The study involves two vaccines: the MenQuadfi vaccine and the Nimenrix vaccine. Both vaccines are designed to protect against four groups of the bacteria: A, C, W, and Y. The purpose of the study is to compare the immune response generated by these vaccines when given to infants at 6 months and again at 12 months.

Participants in the study will receive two doses of either the MenQuadfi vaccine or the Nimenrix vaccine. The first dose will be administered when the infants are between 6 and 7 months old, and the second dose will be given when they are between 12 and 13 months old. The study will monitor the levels of antibodies, which are proteins in the blood that help fight infections, to see how well the vaccines work. The study will also track any side effects or reactions to the vaccines to ensure they are safe for use in young children.

The trial aims to demonstrate that the MenQuadfi vaccine is not less effective than the Nimenrix vaccine in producing an immune response. This will be measured by looking at the levels of antibodies in the blood after vaccination. The study will also observe any immediate or delayed reactions to the vaccines, including any serious adverse events. The results of this study will help determine the best vaccination strategy for protecting young children against meningococcal infection.

]]> Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-survodutide-for-weight-loss-in-adults-with-obesity-without-diabetes/ Mon, 03 Aug 2026 10:36:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-survodutide-for-weight-loss-in-adults-with-obesity-without-diabetes/ This clinical trial is focused on studying the effects of a new treatment for people living with obesity who do not have type 2 diabetes. The treatment being tested is called BI 456906, also known as survodutide, and it is given as a solution for injection under the skin. The purpose of the study is to see if this treatment can help participants lose weight when combined with a reduced-calorie diet and increased physical activity.

Participants in the study will receive either the BI 456906 treatment or a placebo. The study will last for 76 weeks, during which time the effects of the treatment on body weight will be closely monitored. The main goal is to determine if BI 456906 is more effective than the placebo in helping participants achieve weight loss. The study will also look at other health factors, such as changes in waist size and blood pressure.

This trial is designed to provide valuable information about the safety and effectiveness of BI 456906 as a potential treatment for obesity. By participating, individuals will contribute to research that may lead to new ways to manage weight and improve health outcomes for people with obesity.

]]> Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease https://clinicaltrials.eu/trial/study-on-the-effect-of-survodutide-on-heart-safety-in-patients-with-obesity-and-cardiovascular-or-kidney-disease/ Mon, 03 Aug 2026 10:36:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-survodutide-on-heart-safety-in-patients-with-obesity-and-cardiovascular-or-kidney-disease/ This clinical trial is focused on studying the effects of a treatment called BI 456906 on people who are overweight or have obesity. The study is particularly interested in individuals who have existing heart conditions, known as cardiovascular disease (CVD), or chronic kidney disease, and those who have at least two other health issues related to their weight that could increase their risk of heart problems. The treatment, BI 456906, is given as a solution for injection under the skin, a method known as subcutaneous use.

The purpose of the study is to evaluate the safety of BI 456906 in terms of heart health compared to a placebo. Participants will receive either the treatment or a placebo and will be monitored over time to see if there are any differences in the occurrence of heart-related events such as heart attacks, strokes, or heart failure. The study will also look at changes in body weight, blood pressure, and other health markers over a period of time.

Participants in the study will be followed for several weeks, with regular check-ups to monitor their health and any changes that occur. The study aims to provide valuable information on whether BI 456906 is a safe and effective treatment option for people with obesity and related health conditions. The results could help improve the management of obesity and its complications in the future.

]]> Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness https://clinicaltrials.eu/trial/study-on-the-effects-of-human-plasma-proteins-in-adults-with-acute-critical-illness-in-intensive-care/ Mon, 03 Aug 2026 10:33:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-human-plasma-proteins-in-adults-with-acute-critical-illness-in-intensive-care/ This clinical trial aims to evaluate different treatments for patients with acute critical illness who require admission to the intensive care unit. The study will test several medications that are commonly used in intensive care, including different types of blood-thinning medications (enoxaparin, dalteparin, nadroparin, and tinzaparin) given by injection under the skin, as well as human albumin solutions given through a vein.

The study uses a platform design, which means it can evaluate multiple treatments at the same time. Patients will receive one or more of the study medications depending on their specific medical needs. The treatments will be given for up to 90 days while patients are in the intensive care unit.

The study will track various outcomes to determine how well the treatments work, including how long patients survive, how many days they spend without needing life support machines, how many days they spend out of the hospital, and their quality of life after treatment. The study will also monitor patients for any side effects from the medications.

]]> Study on the Effects of Fluorouracil and Capecitabine in Patients with Metastatic Colorectal Cancer https://clinicaltrials.eu/trial/study-on-the-effects-of-fluorouracil-and-capecitabine-in-patients-with-metastatic-colorectal-cancer/ Mon, 03 Aug 2026 10:33:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-fluorouracil-and-capecitabine-in-patients-with-metastatic-colorectal-cancer/ The study focuses on understanding the behavior and treatment outcomes of metastatic colorectal cancer, which is a type of cancer that has spread from the colon or rectum to other parts of the body. The study aims to evaluate how this cancer behaves, its potential for surgical removal, and the recovery and survival of patients after surgery. Two medications are being used in this study: Fluorouracil, which is given as an injection or infusion, and Capecitabine, which is taken as a tablet. Both medications are types of antineoplastic agents, which are drugs used to treat cancer by stopping the growth of cancer cells.

The purpose of the study is to assess the clinical behavior of metastatic colorectal cancer and determine the overall possibility of surgically removing the cancer, as well as to observe any complications after surgery and the outcomes for patients. Participants in the study will receive either Fluorouracil or Capecitabine as part of their treatment plan. The study will monitor the patients over a period to gather information on how well the treatments work and the overall health and recovery of the patients.

This research is important for improving the understanding of metastatic colorectal cancer and finding better ways to treat it. By studying the effects of these medications and the potential for surgery, the study aims to provide valuable insights that could lead to improved treatment strategies and outcomes for patients with this type of cancer.

]]> Study on the Effectiveness of Collagenase, Percutaneous Needle Fasciotomy, and Limited Fasciectomy for Patients with Mild or Moderate Dupuytren’s Contracture https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-collagenase-percutaneous-needle-fasciotomy-and-limited-fasciectomy-for-patients-with-mild-or-moderate-dupuytrens-contracture/ Mon, 03 Aug 2026 10:29:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-collagenase-percutaneous-needle-fasciotomy-and-limited-fasciectomy-for-patients-with-mild-or-moderate-dupuytrens-contracture/ This clinical trial is focused on studying the effectiveness of different treatments for Dupuytren’s contracture, a condition where the fingers bend towards the palm and cannot be fully straightened. The study will compare three treatment methods: collagenase clostridium histolyticum (a medication that helps break down the tough tissue causing the contracture), percutaneous needle fasciotomy (a procedure where a needle is used to cut the cord of tissue causing the contracture), and limited fasciectomy (a surgical procedure to remove the affected tissue).

The purpose of the study is to determine which treatment strategy is the most effective and cost-efficient over a five-year period. Participants will be randomly assigned to one of the three treatment groups. Some participants will receive the collagenase injection, while others will undergo the needle procedure or surgery. The study will follow participants to see how well each treatment works in the short and long term.

Throughout the study, participants will be monitored to assess the success of the treatment they receive. The study aims to provide valuable information on the best approach to managing Dupuytren’s contracture, helping to improve treatment options for this condition in the future.

]]> Prevention of Infantile Spasms with Vigabatrin in High-Risk Children Under 1 Year Old: A Study for Patients with Tuberous Sclerosis or Large Vascular Brain Injury https://clinicaltrials.eu/trial/preventing-infantile-spasms-in-high-risk-infants-using-vigabatrin/ Mon, 03 Aug 2026 10:28:55 +0000 https://clinicaltrials.eu/trial/preventing-infantile-spasms-in-high-risk-infants-using-vigabatrin/ This clinical trial focuses on infantile spasm syndrome, a serious condition that can affect children under one year of age. The study specifically looks at children who are at high risk of developing this condition, including those with tuberous sclerosis (a rare genetic disorder) or those who have experienced significant brain injuries such as large blood vessel damage, severe brain bleeds, or infections affecting the brain tissue.

The study uses vigabatrin, which is given as granules that are mixed with liquid and taken by mouth. This medication will be given as a preventive treatment before any signs of infantile spasms appear. The maximum daily dose is 150 milligrams per kilogram of body weight, and the treatment can continue for up to 11 months.

The main goal of this research is to determine if giving vigabatrin early to high-risk infants can prevent the development of infantile spasm syndrome. The study also looks at how the children’s brain development progresses and uses special eye tracking methods to monitor their development. MRI scans of the brain, which have been performed as part of regular medical care, are used to identify children who might benefit from participating in this research.

]]> Study on Antibiotic Treatment for Uncomplicated Acute Appendicitis Using Levofloxacin, Ertapenem, and Moxifloxacin in Adult Patients https://clinicaltrials.eu/trial/study-on-antibiotic-treatment-for-uncomplicated-acute-appendicitis-using-levofloxacin-ertapenem-and-moxifloxacin-in-adult-patients/ Mon, 03 Aug 2026 10:26:28 +0000 https://clinicaltrials.eu/trial/study-on-antibiotic-treatment-for-uncomplicated-acute-appendicitis-using-levofloxacin-ertapenem-and-moxifloxacin-in-adult-patients/ This clinical trial is focused on studying the treatment of uncomplicated acute appendicitis, a condition where the appendix becomes inflamed but does not have severe complications. The study aims to compare two different approaches to treating this condition using antibiotics. One approach involves taking antibiotics by mouth, known as oral antibiotics, while the other involves starting with antibiotics given through a vein, known as intravenous antibiotics, followed by oral antibiotics.

The antibiotics being studied in this trial include Levofloxacin, Ertapenem, Moxifloxacin, and Metronidazole. Levofloxacin and Moxifloxacin are taken as tablets, while Ertapenem is given as a solution through an infusion, which is a method of delivering medication directly into the bloodstream. Metronidazole is also taken as a tablet. These medications are all antimicrobial agents, which means they are used to treat infections caused by bacteria.

The purpose of the study is to determine if oral antibiotic treatment alone is as effective as the combination of intravenous and oral antibiotics in treating uncomplicated acute appendicitis. Participants in the study will receive one of these treatments, and their progress will be monitored to see if the appendicitis resolves without the need for surgery and does not return within a year. The study will also look at other factors such as any complications after treatment, the length of hospital stay, and the overall quality of life of the participants during the follow-up period.

]]> Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke https://clinicaltrials.eu/trial/study-on-the-effect-of-evolocumab-in-adults-at-high-risk-of-heart-disease-without-previous-heart-attack-or-stroke/ Mon, 03 Aug 2026 10:24:23 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-evolocumab-in-adults-at-high-risk-of-heart-disease-without-previous-heart-attack-or-stroke/ This study focuses on people at high risk of cardiovascular disease who have not previously experienced a myocardial infarction (heart attack) or stroke. The research examines the effectiveness of a medication called evolocumab (also known as AMG 145) compared to placebo in preventing serious heart and blood vessel problems. Evolocumab is a medication that helps lower cholesterol levels in the blood.

The study aims to determine if evolocumab can reduce the risk of death from coronary heart disease, heart attacks, and strokes in people receiving standard cholesterol-lowering therapy. The medication is given as an injection under the skin using a pre-filled pen that contains 140 mg of evolocumab.

During the study, participants will receive either evolocumab injections or placebo injections. The treatment period lasts for 72 weeks, during which participants will continue their usual cholesterol-lowering medications. The study will track various heart-related health events, including arterial revascularization (procedures to restore blood flow in blocked arteries) and death from heart-related causes.

]]> Study on Apixaban for Preventing Blood Clots in Patients Undergoing Abdominal, Gynecologic, and Urologic Surgery https://clinicaltrials.eu/trial/study-on-apixaban-for-preventing-blood-clots-in-patients-undergoing-abdominal-gynecologic-and-urologic-surgery/ Mon, 03 Aug 2026 10:24:15 +0000 https://clinicaltrials.eu/trial/study-on-apixaban-for-preventing-blood-clots-in-patients-undergoing-abdominal-gynecologic-and-urologic-surgery/ This clinical trial is focused on patients undergoing general abdominal, gynecologic, and urologic surgeries. The study is investigating the use of a medication called apixaban, which is an anticoagulant. Anticoagulants are medicines that help prevent blood clots. The trial aims to understand the benefits and risks of using apixaban to prevent blood clots, known as venous thromboembolism (VTE), in patients who are at a similar risk of developing these clots and experiencing bleeding during or after surgery.

Participants in the study will be randomly assigned to receive either apixaban or no anticoagulant treatment. Both groups will receive standard care, which includes mechanical methods to prevent blood clots, such as compression stockings. The study will monitor the occurrence of blood clots and any bleeding complications over a period of 90 days after surgery. The goal is to determine if apixaban provides a net benefit in preventing blood clots without causing significant bleeding.

The trial will also assess the safety of apixaban by tracking any major bleeding events, which could include a significant drop in hemoglobin levels, the need for blood transfusions, or bleeding that requires additional medical intervention. The study will help to clarify whether using apixaban is a safe and effective option for patients undergoing these types of surgeries.

]]> Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ Mon, 03 Aug 2026 10:24:06 +0000 https://clinicaltrials.eu/trial/study-on-zed1227-for-improving-symptoms-in-celiac-disease-patients-on-a-gluten-free-diet/ This clinical trial is focused on studying Celiac Disease, a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, causing damage to the small intestine. The study aims to evaluate the effectiveness and safety of a new treatment called ZED1227, which is taken in the form of a hard capsule. Participants in the trial will either receive the ZED1227 capsules or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to see if ZED1227 can help improve symptoms of Celiac Disease in individuals who continue to experience symptoms despite following a gluten-free diet. The trial will involve participants taking the capsules for a period of 15 weeks. During this time, participants will continue their usual gluten-free diet and will be asked to report their symptoms using a diary specifically designed for Celiac Disease symptoms.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The trial will assess the improvement in symptoms such as diarrhea, abdominal pain, bloating, and nausea, as well as any changes in the condition of the small intestine. The study is designed to provide valuable information on whether ZED1227 can be a beneficial treatment for those with Celiac Disease who are not fully relieved by a gluten-free diet alone.

]]> Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-betula-pollen-extract-for-children-and-adolescents-aged-5-17-with-birch-pollen-allergies-and-possible-asthma/ Mon, 03 Aug 2026 10:23:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-betula-pollen-extract-for-children-and-adolescents-aged-5-17-with-birch-pollen-allergies-and-possible-asthma/ This clinical trial is focused on studying a condition known as birch pollen-induced allergic rhinoconjunctivitis, which is an allergic reaction that affects the nose and eyes, often causing symptoms like sneezing, itching, and watery eyes. The study is also considering participants who have this condition along with asthma. The treatment being tested is called STALORAL® Birch 300 IR, which is an oromucosal solution, meaning it is a liquid that is applied inside the mouth. This treatment contains an extract from birch pollen, which is intended to help the body build a tolerance to the allergen and reduce symptoms over time.

The purpose of the study is to evaluate the safety and effectiveness of STALORAL® Birch 300 IR in children and adolescents aged 5 to 17 years. Participants in the study will be randomly assigned to receive either the STALORAL® Birch 300 IR treatment or a placebo, which is a substance with no active medication. Neither the participants nor the doctors will know which treatment is being given to ensure unbiased results. The study will last for a period of up to 13 months, during which participants will regularly use the treatment and report their symptoms and any changes they experience.

Throughout the study, participants will be monitored to assess how well the treatment works in reducing symptoms of allergic rhinoconjunctivitis and the need for additional medication. The trial aims to provide valuable information on whether STALORAL® Birch 300 IR can be a safe and effective option for managing symptoms in young people with birch pollen allergies, potentially improving their quality of life during the pollen season.

]]> Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems https://clinicaltrials.eu/trial/study-on-balcinrenone-and-dapagliflozin-for-patients-with-heart-failure-and-kidney-problems/ Mon, 03 Aug 2026 10:19:13 +0000 https://clinicaltrials.eu/trial/study-on-balcinrenone-and-dapagliflozin-for-patients-with-heart-failure-and-kidney-problems/ This clinical trial is focused on studying the effects of a treatment for patients with heart failure and impaired kidney function. The treatment being tested is a combination of two medications: Balcinrenone and Dapagliflozin. The study aims to determine if this combination is more effective than using Dapagliflozin alone in reducing the risk of heart-related events and death.

Participants in the study will be randomly assigned to receive either the combination of Balcinrenone and Dapagliflozin or Dapagliflozin alone. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know which treatment each participant is receiving. This helps ensure the results are unbiased. The treatment will be administered in the form of capsules or tablets taken orally.

The study will last for a period of up to 38 weeks, during which participants will be monitored for any heart failure events, hospitalizations, or cardiovascular deaths. The goal is to see if the combination treatment can better prevent these outcomes compared to the single medication. Participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study is expected to provide valuable insights into improving care for patients with heart failure and kidney issues.

]]> Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease https://clinicaltrials.eu/trial/study-on-inclisiran-and-drug-combination-for-preventing-heart-attacks-and-strokes-in-patients-with-cardiovascular-disease/ Mon, 03 Aug 2026 10:18:34 +0000 https://clinicaltrials.eu/trial/study-on-inclisiran-and-drug-combination-for-preventing-heart-attacks-and-strokes-in-patients-with-cardiovascular-disease/ This study focuses on people with atherosclerotic cardiovascular disease, a condition where arteries become narrowed due to buildup of fatty deposits. The research aims to determine if a medication called inclisiran, when combined with standard treatments (atorvastatin or rosuvastatin), can help prevent heart attacks, strokes, and death related to cardiovascular problems.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

]]> Study on Moxifloxacin for Treating Uncomplicated Acute Appendicitis in Adults https://clinicaltrials.eu/trial/study-on-moxifloxacin-for-treating-uncomplicated-acute-appendicitis-in-adults/ Mon, 03 Aug 2026 10:16:59 +0000 https://clinicaltrials.eu/trial/study-on-moxifloxacin-for-treating-uncomplicated-acute-appendicitis-in-adults/ This clinical trial is focused on studying the treatment of uncomplicated acute appendicitis, a condition where the appendix becomes inflamed but has not yet burst or caused severe complications. The study aims to determine if antibiotics can be omitted in treating this condition. Participants will receive either an oral antibiotic called moxifloxacin or a placebo. Moxifloxacin is a type of antibiotic that is commonly used to treat bacterial infections.

The purpose of the study is to compare the effectiveness of the antibiotic treatment with a placebo in managing uncomplicated acute appendicitis. Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving to ensure unbiased results. The study will monitor the participants over a period of 30 days to see if the appendicitis resolves without the need for surgery, known as an appendectomy.

Throughout the study, researchers will also observe any complications that may arise after the treatment, the length of hospital stays, and any readmissions to the hospital. Additionally, they will assess the participants’ pain levels, quality of life, and any costs associated with the treatment. The study will help determine if antibiotics are necessary for treating uncomplicated acute appendicitis or if they can be safely omitted.

]]> Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-upadacitinib-for-patients-with-ulcerative-colitis/ Mon, 03 Aug 2026 10:16:05 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-upadacitinib-for-patients-with-ulcerative-colitis/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called Upadacitinib in people with Ulcerative Colitis. Ulcerative Colitis is a chronic condition that causes inflammation and sores in the lining of the large intestine. The medication being tested, Upadacitinib, is a type of drug known as a Janus kinase (Jak) 1 inhibitor, which works by blocking certain enzymes in the body that are involved in the inflammatory process.

The purpose of this study is to evaluate how safe and effective Upadacitinib is over a long period. Participants in the study will take Upadacitinib in the form of a modified-release tablet, which means the medication is designed to be released slowly in the body. The study will also include a placebo group, which means some participants will receive a tablet that does not contain the active medication. This helps researchers compare the effects of the medication against no treatment.

Throughout the study, participants will be monitored regularly to assess any side effects and to see how well the medication is working in managing their Ulcerative Colitis symptoms. The study is designed to last for several years, allowing researchers to gather comprehensive data on the long-term use of Upadacitinib. Participants will have regular check-ups and assessments to ensure their safety and to track the progress of their condition.

]]> Study Comparing Drug-Coated Balloon and Drug-Eluting Stents in Patients with Coronary Artery Disease at High Risk of Bleeding Using Acetylsalicylic Acid and Drug Combination https://clinicaltrials.eu/trial/study-comparing-drug-coated-balloon-and-drug-eluting-stents-in-patients-with-coronary-artery-disease-at-high-risk-of-bleeding-using-acetylsalicylic-acid-and-drug-combination/ Mon, 03 Aug 2026 10:15:56 +0000 https://clinicaltrials.eu/trial/study-comparing-drug-coated-balloon-and-drug-eluting-stents-in-patients-with-coronary-artery-disease-at-high-risk-of-bleeding-using-acetylsalicylic-acid-and-drug-combination/ This clinical trial is focused on studying treatments for Coronary Artery Disease (CAD), a condition where the blood vessels supplying the heart become narrowed or blocked. The study will compare two different approaches for patients who are at high risk of bleeding and need a procedure called percutaneous coronary intervention (PCI). This procedure is used to open up blocked heart arteries. The trial will look at using a drug-coated balloon (DCB) compared to drug-eluting stents (DES). The goal is to see if the DCB approach, which involves a shorter period of taking two blood-thinning medications, is as effective as the DES approach, which requires a longer period of these medications.

Participants in the study will receive one of the treatments and will be monitored over time to see how well the treatment works and to check for any side effects. The medications involved in the study include Aspirin Cardio, which contains acetylsalicylic acid, Plavix, which contains clopidogrel, Efient, which contains prasugrel, and Brilique, which contains ticagrelor. These medications are commonly used to prevent blood clots in patients with heart conditions.

The study will last for several years, with participants being followed up at different intervals to assess their health and the effectiveness of the treatment. The main focus will be on the occurrence of major heart-related events and bleeding episodes. This research aims to find the best treatment strategy for patients with coronary artery disease who are at high risk of bleeding, ensuring they receive effective care with minimal side effects.

]]> Study on Cabergoline for Pain and Fertility in Women with Endometriosis and Infertility https://clinicaltrials.eu/trial/study-on-cabergoline-for-pain-and-fertility-in-women-with-endometriosis-and-infertility/ Mon, 03 Aug 2026 10:15:18 +0000 https://clinicaltrials.eu/trial/study-on-cabergoline-for-pain-and-fertility-in-women-with-endometriosis-and-infertility/ This clinical trial is focused on studying the effects of the medication cabergoline on women who are experiencing endometriosis and are facing challenges with infertility. Endometriosis is a condition where tissue similar to the lining inside the uterus grows outside of it, often causing pain and fertility issues. The study aims to understand how cabergoline can help reduce pain associated with endometriosis, such as menstrual pain, chronic pelvic pain, and pain during intercourse, and to see if it can improve fertility in women with mild to moderate endometriosis.

Participants in the study will receive either cabergoline or a placebo. Cabergoline is a medication that works by affecting the levels of certain chemicals in the brain, which can help manage symptoms of endometriosis. The study will observe the participants over a period of time to assess changes in their pain levels and fertility status. The goal is to determine if cabergoline can significantly reduce pain and improve the chances of conception in women with endometriosis.

Throughout the study, participants will be monitored to track their pain levels and any changes in their fertility. The study will also evaluate the overall impact of cabergoline on the quality of life for women dealing with endometriosis-related symptoms. This research is important for finding new ways to help women manage the symptoms of endometriosis and improve their chances of becoming pregnant.

]]> Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pembrolizumab-for-patients-with-kidney-cancer-after-surgery/ Mon, 03 Aug 2026 10:15:16 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pembrolizumab-for-patients-with-kidney-cancer-after-surgery/ This clinical trial is focused on studying a type of kidney cancer known as renal cell carcinoma. The study is investigating the use of a medication called pembrolizumab, which is also known by its code name MK-3475. Pembrolizumab is a treatment given through an intravenous infusion, meaning it is delivered directly into the bloodstream. The purpose of the study is to evaluate the safety and effectiveness of pembrolizumab as a treatment option for patients who have had surgery to remove kidney cancer.

Participants in the study will receive either pembrolizumab or a placebo. The study will monitor how long participants remain free of cancer after treatment, which is referred to as disease-free survival. Additionally, the study will look at overall survival, which measures how long participants live after starting the treatment. The study will also track any side effects experienced by participants and whether any participants stop the treatment due to side effects.

The study will take place over a period of time, with participants receiving treatment and being monitored for changes in their health. Regular assessments will be conducted to check for any recurrence of cancer and to evaluate the overall health and quality of life of the participants. The study aims to provide valuable information on the potential benefits of pembrolizumab for patients with renal cell carcinoma following surgery.

]]> Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies https://clinicaltrials.eu/trial/continued-darolutamide-treatment-for-cancer-patients-from-previous-bayer-studies/ Mon, 03 Aug 2026 10:13:21 +0000 https://clinicaltrials.eu/trial/continued-darolutamide-treatment-for-cancer-patients-from-previous-bayer-studies/ This clinical trial focuses on the treatment of cancer using a medication called darolutamide. The study is designed for participants who have already been receiving darolutamide in previous studies sponsored by Bayer. Darolutamide is provided in the form of a film-coated tablet, and the purpose of this study is to continue the treatment for those who are benefiting from it.

Participants in this study will continue taking darolutamide as they have in their previous studies. The study aims to monitor the safety of darolutamide and observe any side effects that may occur during the treatment. The study does not involve any new medications or treatments, and participants will not receive a placebo.

The study will track the occurrence of any treatment-related side effects, including both common and serious ones. It will also look at how often the dosage of darolutamide needs to be adjusted. This study is open-label, meaning that both the participants and the researchers know that darolutamide is being administered. The study will continue until the estimated end date in 2025, allowing participants to maintain their treatment regimen as long as they continue to benefit from it.

]]> Study on Estradiol and Exercise to Reduce Side Effects of Androgen Deprivation Therapy in Prostate Cancer Patients https://clinicaltrials.eu/trial/study-on-estradiol-and-exercise-to-reduce-side-effects-of-androgen-deprivation-therapy-in-prostate-cancer-patients/ Mon, 03 Aug 2026 10:08:22 +0000 https://clinicaltrials.eu/trial/study-on-estradiol-and-exercise-to-reduce-side-effects-of-androgen-deprivation-therapy-in-prostate-cancer-patients/ This clinical trial is focused on studying the effects of treatments for prostate cancer, a common cancer in men. The study will use a treatment called transdermal estradiol, which is a form of estrogen applied to the skin as a gel, and leuprorelin, a medication given by injection. The purpose of the study is to explore how these treatments, along with exercise, can help reduce the side effects of another treatment called androgen deprivation therapy (ADT), which is often used in combination with radiation therapy for prostate cancer.

Participants in the study will receive either the estradiol gel or a placebo, and some will also take part in a six-month exercise program. The study will last for up to one year, during which the effects of the treatments on sexual function, muscle strength, body composition, and overall quality of life will be monitored. The study aims to determine if the estradiol gel can help improve sexual dysfunction and other side effects caused by ADT.

Throughout the study, the safety and tolerability of the treatments will be closely observed. The research will also assess how the combination of estradiol and exercise impacts various health markers, such as muscle and inflammatory biomarkers, which are substances in the blood that can indicate changes in health. The ultimate goal is to find ways to improve the quality of life for men undergoing treatment for prostate cancer.

]]> Study on Atorvastatin’s Effect on Prostate Cancer Progression in Patients Undergoing Androgen Deprivation Therapy https://clinicaltrials.eu/trial/study-on-atorvastatins-effect-on-prostate-cancer-progression-in-patients-undergoing-androgen-deprivation-therapy/ Mon, 03 Aug 2026 10:07:48 +0000 https://clinicaltrials.eu/trial/study-on-atorvastatins-effect-on-prostate-cancer-progression-in-patients-undergoing-androgen-deprivation-therapy/ This clinical trial is focused on studying the effects of the medication atorvastatin on the progression of prostate cancer in patients who are undergoing androgen deprivation therapy (ADT). Prostate cancer is a disease where cancer cells form in the tissues of the prostate, a gland in the male reproductive system. Androgen deprivation therapy is a treatment that reduces male hormones to slow the growth of cancer. The study aims to determine if atorvastatin can delay the progression of prostate cancer, specifically the development of resistance to castration, compared to a placebo during ADT for advanced prostate cancer.

Participants in the study will receive either atorvastatin, a cholesterol-lowering drug, or a placebo, which is an identical capsule without any active ingredient. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are not influenced by expectations or bias. The trial will monitor the time it takes for the disease to progress after starting ADT or antiandrogen therapy.

The study will take place over a period of time, with regular check-ups to assess the health and progress of the participants. The goal is to gather information on whether atorvastatin can be an effective addition to the treatment of prostate cancer, potentially offering a new way to manage the disease and improve patient outcomes. Participants will be closely monitored throughout the study to ensure their safety and well-being.

]]> Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke https://clinicaltrials.eu/trial/study-on-asundexian-and-apixaban-for-preventing-stroke-in-adults-with-atrial-fibrillation-at-risk-for-stroke/ Sun, 02 Aug 2026 04:01:07 +0000 https://clinicaltrials.eu/trial/study-on-asundexian-and-apixaban-for-preventing-stroke-in-adults-with-atrial-fibrillation-at-risk-for-stroke/ This clinical trial is focused on studying the prevention of stroke or systemic embolism in people with atrial fibrillation, a condition where the heart beats irregularly and often rapidly. The study is comparing two treatments: asundexian (also known by its code name BAY 2433334) and apixaban, which is marketed under the name Eliquis. Both medications are taken orally in the form of film-coated tablets. The purpose of the study is to determine how well asundexian works and how safe it is compared to apixaban in preventing stroke or systemic embolism in individuals with atrial fibrillation who are at risk for stroke.

Participants in the study will be randomly assigned to receive either asundexian or apixaban. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of up to 33 days, during which the safety and effectiveness of the treatments will be closely monitored.

The main goal is to see if asundexian is at least as effective as apixaban in preventing stroke and systemic embolism, and to assess the risk of major bleeding, which is a significant concern with blood-thinning medications. The study will also look at other outcomes, such as the occurrence of minor bleeding, cardiovascular events, and overall mortality. This research aims to provide valuable information on the potential benefits and risks of asundexian compared to apixaban for people with atrial fibrillation at risk of stroke.

]]> Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease https://clinicaltrials.eu/trial/randomized-phase-iii-trial-of-elecoglipron-plus-dapagliflozin-on-kidney-outcomes-and-mortality-in-adults-with-chronic-kidney-disease/ Sun, 26 Jul 2026 04:03:18 +0000 https://clinicaltrials.eu/trial/randomized-phase-iii-trial-of-elecoglipron-plus-dapagliflozin-on-kidney-outcomes-and-mortality-in-adults-with-chronic-kidney-disease/ The study looks at adults with Chronic kidney disease (CKD), a condition where the kidneys gradually lose their ability to filter waste. Participants may have a range of kidney function measured by eGFR, which estimates how well the kidneys filter blood, and may show protein in the urine. All participants will continue taking the standard medication dapagliflozin at a dose of 10 mg daily, while the experimental drug Elecoglipron (code name AZD5004) or a matching placebo will be given as an oral tablet.

The aim of the trial is to see whether adding the experimental drug reduces the chance of a large and lasting drop in kidney function, the development of end-stage kidney disease (very low kidney function requiring dialysis or transplant), or death from any cause. Participants will be randomly assigned to receive either the study drug or placebo, will take the assigned tablet each day, and will be monitored with regular clinic visits, blood tests, and urine checks over several years to record any health events.

]]> University Of Jyvaskyla https://clinicaltrials.eu/site/university-of-jyvaskyla/ Tue, 02 Jun 2026 09:57:14 +0000 https://clinicaltrials.eu/site/university-of-jyvaskyla/ StudyCor Oy https://clinicaltrials.eu/site/studycor-oy/ Tue, 12 May 2026 06:15:07 +0000 https://clinicaltrials.eu/site/studycor-oy-2/ Central Finland Hospital District Central Finland Hospital Nova https://clinicaltrials.eu/site/central-finland-hospital-district-central-finland-hospital-nova/ Tue, 12 May 2026 06:14:37 +0000 https://clinicaltrials.eu/site/central-finland-hospital-district-central-finland-hospital-nova-2/ Suomen Terveystalo Oy https://clinicaltrials.eu/site/suomen-terveystalo-oy-7/ Tue, 12 May 2026 06:08:11 +0000 https://clinicaltrials.eu/site/suomen-terveystalo-oy-7/ Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History https://clinicaltrials.eu/trial/study-on-selatogrel-for-preventing-heart-attack-in-patients-with-recent-heart-attack-history/ Wed, 29 Apr 2026 14:57:27 +0000 https://clinicaltrials.eu/trial/study-on-selatogrel-for-preventing-heart-attack-in-patients-with-recent-heart-attack-history/ This clinical trial is focused on studying acute myocardial infarction, commonly known as a heart attack. The study is evaluating a treatment called Selatogrel, which is a solution for injection that participants can administer themselves using a pre-filled injector. The purpose of the study is to assess how effective and safe Selatogrel is when used to prevent death from any cause and to treat heart attacks in people who have recently experienced one.

Participants in the study will be randomly assigned to receive either Selatogrel or a Selatogrel matching placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow participants over a period to observe the occurrence of death or another heart attack after they have self-administered the treatment.

The study will also monitor for any safety concerns, such as bleeding events, that may occur within two days after taking the treatment. Additionally, researchers will look at other outcomes like hospital visits for heart failure within 30 days after treatment. This trial aims to provide valuable information on the potential benefits and risks of using Selatogrel for individuals at risk of having another heart attack.

]]> Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments https://clinicaltrials.eu/trial/study-on-the-effect-of-obicetrapib-in-patients-with-atherosclerotic-cardiovascular-disease-not-adequately-managed-by-current-lipid-lowering-treatments/ Wed, 29 Apr 2026 14:26:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-obicetrapib-in-patients-with-atherosclerotic-cardiovascular-disease-not-adequately-managed-by-current-lipid-lowering-treatments/ This clinical trial is focused on studying the effects of a medication called Obicetrapib in people with atherosclerotic cardiovascular disease (ASCVD). ASCVD is a condition where the arteries become narrowed due to the buildup of plaque, which can lead to serious heart and blood vessel problems. The study aims to see how well Obicetrapib works in reducing the risk of major heart-related events, such as heart attacks, strokes, or the need for certain heart procedures, in participants whose current treatments are not fully effective.

Participants in the study will receive either Obicetrapib or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their health and any changes in their condition.

The goal of the study is to gather information on how Obicetrapib affects the risk of serious cardiovascular events in people with ASCVD. By participating, researchers hope to better understand the potential benefits of this medication for those who are not adequately helped by their current treatments. The study will provide valuable insights into the effectiveness of Obicetrapib in managing heart and blood vessel health in individuals with this condition.

]]>